Inside this issue you will find:

- Clinical Research at Deborah
- New and Exciting Clinical Research Studies at Deborah
- Deborah Specialists in Local Communities

DEBORAH® Heart and Lung Center

© Gore and Associates, Inc.
Two years ago Deborah Heart and Lung Center made the decision to build on its robust clinical research division and formally dedicated a Clinical Research Department. Research at Deborah has traditionally been one of the hospital’s strategic capabilities, supporting both the clinical and educational missions of the hospital. To promote the performance of top tier research studies at Deborah, a vigorous process is instituted prior to the approval of any new research studies. This four-tiered protocol review includes: administrative, scientific, financial and patient safety parameters.

Deborah’s Clinical Research Department is administered by Medical Director Jon C. George, M.D., Attending, Interventional Cardiology, NIH Researcher and Gail Anolik, RN, PhD, CPHQ, Administrative Director. The Department staff, including six Coordinators, works closely with Principal Investigators and Sub-Investigators to initiate new studies and manage current projects. The Department currently has 35 exciting research studies spanning clinical cardiology, interventional cardiology, electrophysiology, and peripheral vascular disease.

States Dr. George: “In addition to being part of the wave of the future, with our involvement in these exciting research projects, we usually have the first opportunity to offer cutting-edge treatment options to our patients. This is a great benefit to the residents of New Jersey and the Delaware Valley, who now have access to the latest medical innovations.”

“These exciting research projects allow Deborah the opportunity to offer cutting-edge treatments to our patients.”
New and Exciting Clinical Research Studies at Deborah

**Evolve II**
This study is designed to assess the safety and effectiveness of the new SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System for the treatment of patients with atherosclerotic lesions. The study will compare SYNERGY with the current state-of-the-art Promus element stent, which offers deliverability and low restenosis rates. The SYNERGY stent promises flexibility for treating patients with difficult anatomy, improved deliverability to shorten procedure times, as well as less radiation exposure and contrast administration.

*Sponsored by Boston Scientific Corporation*

**LEVANT 2 (Continued Registry)**
This study was designed to demonstrate the superior efficacy and non-inferior safety of the Moxy Drug Coated Balloon by direct comparison to standard PTA catheter for treatment of stenosis of the femoropopliteal arteries. Patients enrolled included those with claudication or ischemic rest pain, and significant disease of the superficial femoral or popliteal artery. Those patients who did not require stenting received the Moxy Drug Coated Balloon, with results analyzed at one year, and patients receiving follow-up study for five years.

*Sponsored by Lutonix, Inc.*

**EXCITE**
The EXCITE ISR trial is designed to collect information on the safety and efficacy of Excimer Laser Atherectomy (ELA) with the standard treatment of balloon angioplasty (PTA) in patients that have restenosis of a previously placed stent in the superficial femoral artery of the leg. Patients are randomized into ELA with PTA or PTA alone.

*Sponsored by Spectranetics Corporation*

**Analyze ST**
This study expands the functionality capability of an ICD device to protect patients from arrhythmic events and potential tissue damage from ischemia. Eligible patients will have an opportunity to join the current Angèl Med Alert Trial which targets patients with preserved ejection fraction and coronary artery disease, but excludes patients that meet criteria for an ICD. The Analyze ST participants will meet criteria for an ICD and be at high risk for developing CAD, or have existing CAD.

*Sponsored by St. Jude Medical*

**GORE FREEDOM Study**
This two-armed study provides ongoing evaluation of clinical outcomes associated with the GORE Flow Reversal System and the GORE Embolic Filter, when used for embolic protection during carotid stenting. The GORE Flow Reversal System is designed to provide proximal protection during carotid angioplasty and stenting in patients diagnosed with carotid stenosis with certain anatomical criteria. The GORE Embolic Filter is indicated for use as a guide wire and embolic protection system to contain and remove thrombus/debris during carotid interventions. Patients will be enrolled into one of the two arms of the study, which is designed not as a comparison, but to evaluate the treatment outcomes of each of these commercially-available embolic protection devices.

*Sponsored by W. L. Gore & Associates*
The vascular surgeons and cardiology specialists at Deborah Heart and Lung Center in Browns Mills, NJ, offer a wide array of state-of-the-art diagnostic and treatment services to patients. Additionally, our specialists are also available to see your patients in their private practice offices for their convenience in Toms River and Manahawkin, NJ.

Recent expansion of vascular services in the Toms River offices now includes the Advanced Vein Center for treatment of varicose veins. Office locations including vascular and cardiovascular services are in the following locations:

**Toms River Office:**
Advanced Vascular Surgery and Advanced Vein Center  
Advanced Thoracic Surgery  
Advanced Electrophysiology  
25 Mule Road, Suite B5, Toms River, NJ 08753  
Phone: 732-557-0080 • Fax: 732-557-5016

**Manahawkin Office:**
Advanced Vascular Surgery  
Advanced Cardiology  
Advanced Electrophysiology  
73 Nautilus Drive, Manahawkin, NJ 08050  
Phone: 609-597-4479 • Fax: 609-597-8382